Navigation Links
The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research

WHITE PLAINS, N.Y., July 6 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and The International Waldenstrom's Macroglobulinemia Foundation (IWMF) have partnered in an initiative to develop stable and immortalized Waldenstrom's macroglobulinemia (WM) cell lines that would be made widely available to researchers to test potential new treatments for the disease.

WM occurs as low-grade B-cell non-Hodgkin lymphoma, characterized by B-lymphocytes in the bone marrow, and an abnormal level of the protein monoclonal immunoglobulin M (IgM). Though the disease is slow-growing, a curative treatment has yet to be developed. Cell lines are invaluable in understanding the genetics and biology of cancerous cells. The development of a biologically stable and satisfactorily representative WM cell line will enable researchers throughout the world to test their latest ideas on bio-identical cells and thus compare their results with those of other researchers.

Researchers agree that new cell lines are urgently needed as it is widely understood that the three most used existing WM cell lines may not accurately represent the disease.

"Numerous scientists studying WM report that one of the barriers to finding a cure is the lack of a standardized WM cell line," said LLS Chief Scientific Officer Louis J. DeGennaro, Ph.D. "Together, LLS and IWMF are committed to seeing this critical asset developed in a way so as not to fundamentally change the cellular and functional characteristics of the original tumor, and thus enable researchers to better understand the unique aspects of WM biology and advance more effective treatments for WM patients."

Under the agreement, LLS and IWMF will seek applications and select up to three laboratories to co-fund for up to $100,000 for one year. Continued funding, potentially for up to two additional years, will be contingent on available funds and assessments of progress toward the goal of developing suitable cell lines.

"IWMF has funded several research projects where WM cell lines have been utilized," said Tom Meyers, Ph.D., IWMF vice president of research. "In most cases it is difficult to compare some of the research results because the cell lines are different. This will no longer be the case if this cell line development is successful."

To read about the request for applications or to fill out an application, please visit the following links:

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

About The International Waldenstrom's Macroglobulinemia Foundation

The IWMF was started in 1994 when Arnold Smokler, a pharmacist, developed the disease and could find little information about it. Initially, he formed a support group in the Washington, D.C. area. By 1998 the organization had grown substantially and it was incorporated in Florida as a non-profit corporation under its current name. The organization has continued to grow with worldwide membership of nearly 4,000. The IWMF provides support to patients and their caregivers, enables patients and caregivers to communicate with one another, sponsors educational forums on the disease featuring prominent doctors and researchers associated with the disease, publishes booklets on the disease and its treatment and supports research aimed at understanding the disease and, ultimately finding a cure. Since 2000, nearly $4 million has been given to institutions conducting research on the disease.

    Contact: Andrea Greif, (914) 821-8958

SOURCE The Leukemia & Lymphoma Society
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
2. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
3. Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
4. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
5. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
6. In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia
7. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
8. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
9. Not the protein, but its location in the cell, determines the onset of leukemia
10. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
11. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
Post Your Comments:
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
Breaking Biology News(10 mins):